Lung Cancer Clinical Trials & Research at Providence Medical Group
The two main types of lung cancer are non-small cell lung cancer and small
cell lung cancer. The types are based on the way the cells look under
a microscope. Non-small cell lung cancer is much more common than small
cell lung cancer. Tobacco smoking is the most common cause of lung cancer.
Providence Medical Group is currently enrolling patients for the following
lung cancer clinical trials:
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy
With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer
Patients Who Are PD-L1 Negative (Alliance A082002)
Treatment agent: Radiotherapy + Immunotherapy (+/- Chemotherapy)
Physician:
Michael N. Corradetti
Study Coordinator: Camille Shaffer //
camille.shaffer@stjoe.org // 707-521-3830
Study Resources:
https://clinicaltrials.gov/study/NCT04929041
Sponsor: National Cancer Institute (NCI) / Alliance for Clinical Trials
in Oncology
Location: Providence Queen of the Valley Medical Center, Napa, CA
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy
in First-line HER2 Overexpressing Non-small Cell Lung Cancer (DESTINY-Lung06)
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy
for First-Line Treatment of Metastatic Non-squamous NSCLC
Treatment agent: Rilvegostomig (AZD2936) - D702FC00001
Physician:
Ian Anderson, MD
Study Coordinator: Tracy Foster //
tracy.foster@stjoe.org // 707-521-3830
Study Resources:
Study Details | A Global Phase III Study of Rilvegostomig or Pembrolizumab
Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous
NSCLC | ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA
A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations
in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (ALTAIR)
Treatment agent: AB248
Physician:
Ian Anderson, MD
Study Coordinator: Tracy Foster //
tracy.foster@stjoe.org // 707-521-3830Study Resources:
Sponsor:
Location: Providence Cancer Center, Santa Rosa, CA
A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With
or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for
Participants with EGFR-mutated Locally Advanced or Metastatic Non-small
Cell Lung Cancer whose Disease has Progressed on Prior Osimertinib Treatment
(TROPION-Lung15)